Summer Collection

Glow – 70mg, NAD+ 500mg, RT-GLP3 – 10mg, FREE Bacteriostatic Water

The ultimate summer research collection featuring three of our most popular compounds.

Glow – 70mg.

The Glow Blend is a composite research formulation integrating three mechanistically distinct peptides — BPC-157 (10mg), TB-500 (10mg), and GHK-Cu (50mg) — frequently examined in regenerative and cytoprotective research models. BPC-157 is a 15-amino acid peptide fragment originally isolated from mammalian gastric juice, investigated for its potential role in nitric oxide pathway modulation, growth factor signaling, and extracellular matrix remodeling. TB-500 is a synthetic peptide corresponding to a 43-amino acid sequence of thymosin beta-4, studied for its involvement in actin binding, cytoskeletal organization, cell migration, and angiogenesis. GHK-Cu (Copper Tripeptide) is a naturally occurring tripeptide present in blood plasma with a sequence of Gly-His-Lys that readily binds copper. Research suggests GHK-Cu may influence tissue repair, collagen and glycosaminoglycan synthesis, antioxidant and anti-inflammatory pathways, and extracellular matrix regulation. Together, these three peptides target cellular repair signaling, angiogenic modulation, and extracellular matrix remodeling through complementary biological pathways.

NAD+ – 500mg.

NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme found in every living cell and is central to cellular metabolism and energy homeostasis. It plays a critical role in converting nutrients into cellular energy in the form of ATP through mitochondrial respiration, and serves as an essential cofactor for two key enzyme families: sirtuins and PARPs. Sirtuins are proteins linked to longevity that help regulate inflammation, support mitochondrial biogenesis, maintain DNA stability, and improve cellular stress response. PARPs are enzymes responsible for detecting and repairing damaged DNA strands, protecting cells from aging-related mutations. NAD+ levels naturally decline with age, correlating with reduced metabolic function, impaired DNA repair capacity, and increased susceptibility to oxidative stress. Research by Dr. David Sinclair at Harvard Medical School has demonstrated that restoring NAD+ levels in animal models through precursors like NMN may improve mitochondrial function, enhance DNA repair, increase muscle endurance, and partially reverse age-related tissue decline. NAD+ represents a foundational molecule in longevity and cellular resilience research.

Retatrutide – 10mg.

Retatrutide (LY3437943) is a 39-amino-acid synthetic triple receptor agonist engineered from a GIP peptide backbone. It simultaneously activates the glucagon receptor (GCGR), glucagon-like peptide-1 receptor (GLP-1R), and glucose-dependent insulinotropic polypeptide receptor (GIPR) — three pivotal receptors involved in metabolic regulation. Its structure incorporates non-coded residues (Aib2, Aib20, α-MeLeu13) and a C20 fatty diacid conjugation to enhance stability and extend systemic presence through albumin binding. In preclinical models, Retatrutide has been shown to induce cAMP accumulation, decrease plasma glucose levels, and reduce body weight, calorie intake, and fat mass in a dose-dependent manner. Phase 2 clinical data demonstrated significant improvements in glycemic control and robust reductions in bodyweight with a safety profile consistent with existing GLP-1 receptor agonist therapies. Retatrutide represents a next-generation approach in metabolic research, building upon the dual-agonist framework established by compounds like tirzepatide.